Cabaletta Bio (NASDAQ:CABA) Trading 10.3% Higher - Should You Buy?

Key Points

• Cabaletta Bio shares rose 10.3% to $3.21 amid improved HC Wainwright earnings forecasts, including narrower projected losses for 2026–2028.
• Analyst sentiment is mixed but leans positive: the stock has a consensus “Moderate Buy” rating and a $15.33 target price, despite Wells Fargo lowering its target to $3 and other firms maintaining sell or hold ratings.
• The company remains unprofitable, with analysts expecting a $1.34-per-share loss this year; however, Cabaletta beat its latest quarterly EPS estimate and HC Wainwright projects a potential return to profitability by 2030.

Shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) shot up 10.3% on Wednesday . The stock traded as high as $3.09 and last traded at $3.21. 1,342,561 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 3,731,450 shares. The stock had previously closed at $2.91.

Key Headlines Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright improved its EPS forecasts for several periods, including Q3 and Q4 2026, Q1–Q4 2027, FY2026 and FY2027. The firm now expects a loss of $1.35 per share in FY2026 versus its prior forecast of $1.51, and a loss of $1.29 in FY2027 versus $1.48 previously. These narrower projected losses suggest better expected operating performance and are likely supporting sentiment toward Cabaletta Bio (CABA). Cabaletta Bio stock information
• Positive Sentiment: The most significant revision was for FY2028, with HC Wainwright moving its estimate to a $0.74-per-share loss from a $1.41 loss. The firm continues to forecast a transition to profitability by FY2030, with expected earnings of $0.89 per share, reinforcing the longer-term potential of Cabaletta Bio’s pipeline.
• Neutral Sentiment: Despite the upgrades, Cabaletta Bio is still expected to report losses in the coming periods, including approximately $0.31 per share in quarterly losses during late 2026 and early 2027. The current-year consensus remains a loss of $1.34 per share, so investors are likely focused on the pace of improvement rather than near-term profits.
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS forecast to a $0.68 loss from a $0.64 loss and cut its FY2030 earnings forecast to $0.89 from $1.11. These downward long-term revisions temper the bullish impact of the nearer-term upgrades and highlight uncertainty around Cabaletta Bio’s path to sustainable profitability.

Analyst Ratings Changes

CABA has been the subject of a number of research reports. Wells Fargo & Company cut their price target on shares of Cabaletta Bio from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Friday, August 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Cabaletta Bio in a report on Monday, May 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cabaletta Bio in a research report on Friday, July 17th. Wall Street Zen cut Cabaletta Bio from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Finally, Jefferies Financial Group restated a "buy" rating on shares of Cabaletta Bio in a research report on Wednesday, June 3rd. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.33.

Cabaletta Bio Trading Up 6.7%

The company has a market capitalization of $526.42 million, a PE ratio of -1.98 and a beta of 3.30. The firm has a fifty day moving average of $2.87 and a two-hundred day moving average of $3.06.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. On average, equities analysts expect that Cabaletta Bio, Inc. will post -1.34 EPS for the current fiscal year.

Institutional Trading of Cabaletta Bio

A number of institutional investors have recently modified their holdings of CABA. Kestra Advisory Services LLC purchased a new position in Cabaletta Bio during the 1st quarter valued at about $32,000. SummitTX Capital L.P. purchased a new stake in Cabaletta Bio in the 1st quarter worth approximately $34,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $34,000. Legal & General Group Plc bought a new stake in shares of Cabaletta Bio in the 2nd quarter worth approximately $34,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in shares of Cabaletta Bio in the 4th quarter worth approximately $38,000.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source